Neuro

Balt Announces Publication in New England Journal of Medicine of The Squid Trial for the Embolization of the Middle Meningeal Artery (STEM) for the Treatment of chronic Sub-Dural Hematoma

Neuro by Comments are Disabled

BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) — Balt, Inc., a global technology leader in neurovascular devices, today announced the publication of The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma in the New England Journal of Medicine. The study shows that among patients with symptomatic chronic subdural hematoma (cSDH), adjunctive middle meningeal artery (MMA) embolization resulted in a lower risk of treatment failure than standard treatment alone, without resulting in an increased incidence of disabling stroke or death in the short term. STEM is the first randomized prospective IDE trial investigating embolization of the MMA for the treatment of cSDH.

Continue Reading →

NeuroVascular Quality Initiative Quality Outcomes Database (NVQI-QOD) Celebrates 25,000th Procedure Milestone

Neuro by 0 comments

NeuroVascular Quality Initiative Quality Outcomes Database (NVQI-QOD) Celebrates 25,000th Procedure Milestone FAIRFAX, Va.– The Society of NeuroInterventional Surgery’s (SNIS) Patient Safety Organization (PSO), in partnership with the NeuroPoint Alliance (NPA), is pleased to announce that the NVQI-QOD has recorded more than 25,000 procedures in the registry. This significant milestone underscores […]

Continue Reading →

RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position

Neuro by Comments are Disabled

RapidAI’s leadership is evident in its expansive global presence, pioneering regulatory achievements, and continuous innovation, ensuring the company remains at the forefront of AI-based imaging solutions. SAN ANTONIO, Oct. 30, 2024 /PRNewswire/ — Recently Frost & Sullivan researched the…

Continue Reading →

The 21st World Congress of Chinese Medicine – Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris

Coronary/Structural Heart Neuro by Comments are Disabled

PAIRS, Oct. 28, 2024 /PRNewswire/ — On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. A key highlight of the WCCM was the Seminar on the…

Continue Reading →

Remedy Pharmaceuticals Announces FDA Orphan Drug Designation Granted for the Treatment of Large Territory Acute Ischemic Stroke with CIRARA

Neuro by Comments are Disabled

NEW YORK, Oct. 22, 2024 /PRNewswire/ — Remedy Pharmaceuticals, a pioneer in stroke drug development, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation for CIRARA for the treatment of “large…

Continue Reading →

NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)

Neuro by Comments are Disabled

SANTA ANA, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced acceptance of an oral presentation on the potential of troculeucel in patients with neurodegenerative disease and stroke, at the 16th World Stroke Congress (“WSC 2024”) to be held in Abu Dhabi, UAE from October 23–26, 2024. Although accepted as an oral presentation, NKGen has opted to showcase troculeucel results in poster format.

Continue Reading →
1 … 10 11 12 13 14 … 51